CNS Pharmaceuticals
CNSP

$1.07

4.42%

Market Cap: 3.07M

About: CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Employees: 3

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

0

News positive %

of 3 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

700% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 1

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

19% more funds holding

Funds holding: 16 [Q4 2023] → 19 (+3) [Q1 2024]

6.15% more ownership

Funds ownership: 5.39% [Q4 2023] → 11.54% (+6.15%) [Q1 2024]

17% less capital invested

Capital invested by funds: $425K [Q4 2023] → $351K (-$74.3K) [Q1 2024]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for CNSP.

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CNSP published over the past 30 days

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

HOUSTON, TX / ACCESSWIRE / July 25, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that its abstract has been selected for poster presentation at the 2024 SNO/ASCO CNS Cancer Conference being held August 8-10, 2024 in Denver, CO. Details of the presentation are as follows: Title: Use of a Brain-Penetrating Anthracycline in Anthracycline-Sensitive Brain Metastases: The Promise of Berubicin Presenter: Sandra Silberman, MD, PhD, Chief Medical Officer of CNS Pharmaceuticals Abstract Code: RMTD-03 Category: Research Methods and Trial Design Considerations Date and Time: August 8, 2024 from 7:15 - 9:00 PM MT Location: Plaza Exhibit Hall, Sheraton Denver Downtown Hotel For more information about the event, please visit the conference website.

CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

Live video webcast with Chief Executive Officer, John Climaco, on Wednesday, June 17th at 4:00 PM ET HOUSTON, TX / ACCESSWIRE / July 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in the Virtual Investor Closing Bell Series on Wednesday, June 17, 2024 at 4:00 PM ET. As part of the event, Mr.

CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

HOUSTON, TX / ACCESSWIRE / July 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 1,425,000 shares of common stock in a registered direct offering and warrants to purchase up to 1,425,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $1.39 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $1.26 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

HOUSTON, TX / ACCESSWIRE / June 26, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 568,000 shares of common stock in a registered direct offering and warrants to purchase up to 568,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $2.45 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $2.32 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

HOUSTON, TX / ACCESSWIRE / June 14, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 366,000 shares of common stock (or common stock equivalents in lieu thereof) in a registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement (together with the registered direct offering, the "Offering") at a combined purchase price of $3.75 per share. The warrants issued pursuant to the concurrent private placement will have an exercise price of $3.62 per share, will be exercisable immediately following the date of issuance and will expire 5 years from the initial exercise date.

CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement

CNS Pharmaceuticals Announces Reverse Stock Split

HOUSTON, TX / ACCESSWIRE / June 3, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024. Beginning on June 5, 2024, the Company's common stock will continue to trade on The Nasdaq Capital Market ("Nasdaq") on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H300.

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

Live webcast fireside chat on Tuesday, May 21st at 1:40 PM ET HOUSTON, TX / ACCESSWIRE / May 20, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET. A live webcast of the event will be on the Events page of the Investors section of the Company's website (cnspharma.com).

CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

Enrollment completed in potentially pivotal GBM study evaluating Berubicin; Topline data expected in first half of 2025 Company committed to addressing the most aggressive type of brain cancer with an average survival of only 14 to 16 months after diagnosis and no cure HOUSTON, TX / ACCESSWIRE / May 16, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the first quarter 2024 ended March 31, 2024. "With topline results in our ongoing, fully enrolled Berubicin trial for GBM expected in the first half of next year, we continue to plan for success.

CNS Pharmaceuticals Reports First Quarter 2024 Financial Results

CNS Pharmaceuticals to Present at the LSX World Congress 2024

Presentation on Monday, April 29th at 4:15 PM (GMT+1) HOUSTON, TX / ACCESSWIRE / April 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM (GMT+1) in London, England. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

CNS Pharmaceuticals to Present at the LSX World Congress 2024

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

Live video webcast with Chief Executive Officer, John Climaco, on Tuesday, April 23rd at 12:00 PM ET HOUSTON, TX / ACCESSWIRE / April 22, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor Lunch Break: The CNSP Opportunity event on Tuesday, April 23, 2024 at 12:00 PM ET. As part of the event, Mr.

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity

See News Rankings